The median progression-free survival was 22.1 months in the pyrotinib arm and 10.5 months in the control arm. Adding pyrotinib to trastuzumab and docetaxel can prolong progression-free survival (PFS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback